Advertisement

Reinventing Quality of Life: Refining the Concept and Going Beyond Assessments

  • A. George AwadEmail author
Chapter

Abstract

In spite of the broad popularity of the concept of quality of life in medicine and generally in its broad societal usage, why then is the interest in measuring quality of life in schizophrenia has been somewhat eroded in recent years? Obviously, there is no single answer to such a challenging question, but it seems to relate to a number of issues specific to the schizophrenia disorder itself and its impact on a wide range of mental deficits, as well as the impact of its treatment, i.e., the various and significant side effects of antipsychotic medications. Equally significant is the lack of research interest to go beyond assessments of quality of life into the broader applications that can impact clinical management and other important health outcomes. The excellent contributions to this book by the various internationally known experts in the field, coming from a broad range of theoretical and scientific background, all attest that the concept of quality of life in schizophrenia is alive and continues to be of great interest, but requires to be invigorated. New conceptual thinking, refinement of methodology, and going beyond measurement, into researching models for integration in clinical care as well as in pharmaco- and health economics, are all needed.

Keywords

Antipsychotic Medication Item Bank Experience Sampling Method Conceptual Thinking Important Health Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Calman KC. Quality of life in cancer patients – an hypothesis. J Med Ethics. 1984;10:124–7.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Philips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry. 2006;67:1937–403.CrossRefGoogle Scholar
  3. Voruganti LNP, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - Findings from an in vivo SPECT study. Schizophre Res. 2006;88:178–86.Google Scholar
  4. Voruganti LNP, Awad AG. Role of dopamine in pleasure, reward and subjective responses to drugs – the neuropsychopharmacology of quality of life in schizophrenia. In: Ritsner M, Awad AG, editors. Quality of life impairment in schizophrenia, mood and anxiety disorder. Dordrecht: Springer; 2007. p. 21–31.Google Scholar
  5. Voruganti LNP, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG. Subjective effects of AMPT - induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging. Neuro Psychopharmacology. 2001;25:642–50.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Psychiatry, The Institute of Medical ScienceUniversity of TorontoTorontoCanada

Personalised recommendations